Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
about
Platinum-induced hearing loss after treatment for childhood cancerPharmacogenomics in Pediatric Patients: Towards Personalized MedicineAn integrated view of cisplatin-induced nephrotoxicity and ototoxicityProgress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityGene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patientsImpact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose.Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastomaPharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.Advances in the Pharmacogenomics of Adverse Drug Reactions.Ototoxicity and cancer therapy.The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies.Personalized medicine: Genetic risk prediction of drug response.TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.Novel insights and therapeutic interventions for pediatric osteosarcoma.Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.Ototoxicity monitoring in children treated with platinum chemotherapy.Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.Genetic testing for the risk of developing late effects among survivors of childhood cancer: Consumer understanding, acceptance, and willingness to pay.Interactions between ACYP2 genetic polymorphisms and environment factors with susceptibility to ischemic stroke in a Han Chinese Population.Long-term toxicity of cisplatin in germ-cell tumor survivors.Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors.Ototoxicity: A Challenge in Diagnosis and Treatment.Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.Association of ACYP2 and TSPYL6 Genetic Polymorphisms with Risk of Ischemic Stroke in Han Chinese Population.
P2860
Q26470526-D6900F13-3595-4409-A0FF-A2D7C1F2034CQ28071448-5DFBBEFB-382F-4E2D-953F-0E8AC4118254Q28080615-0D62E545-EE12-4AAA-B2D5-A2C44C431346Q28083100-B44A88CB-00F8-4C82-8C4A-C39A8DC43904Q33894826-C19B3FFF-6208-4E2A-BF01-B0CCDC43767DQ34549324-9809EFF6-378E-42AE-89D7-C5693E0BD2D9Q36035287-05319A42-1E56-4284-96F1-973B09CCFCECQ36358551-3B457A4B-7F6B-4BCF-8C5C-EDF0495B9F5EQ38637751-BEB88757-9B81-4D58-8299-C721BF4CE77FQ38663764-F76B5CA6-90AB-4DF1-BA06-B3F0D5E4B3D8Q38727368-923F11C3-2047-402A-A998-CD910704676FQ38739253-956F2309-E2CF-4236-8E43-372D7C075B73Q38756015-D8963A0C-BCB3-4C86-9619-D1C4D3CA97BFQ38818727-3729975E-3368-4F24-A13E-0C3776F5146BQ38819276-7E106199-6C61-4D47-A13F-4737A2FDFAB1Q38909984-D8EFE7CC-C327-4A53-BAA5-6F0B6CF0D25AQ39262358-DF093791-4381-4CA4-A49F-E38CD977FD85Q39453840-32372F1D-9C2F-4DF1-8480-6FED5732E8F5Q40600080-2B5E35C5-B937-44FD-857B-BB77DD6058D7Q40720451-B83B4DB2-3DBA-486D-BF97-F80BB1D4CBF5Q47112960-E2B704F1-A3DC-4E47-A041-3FC8BACB7F3FQ47239998-58BC89B1-54C2-4FD5-BE98-7439BE533FFCQ47819341-49B229C2-E092-4A95-9281-43F2C4FCFAEDQ48659411-006ACDF5-03A1-4AAC-90CB-BD137DCC78F9Q50300972-107309AD-C1AC-4FBC-9943-10181ABF4686Q50313675-5CE86517-62A8-4998-9ADC-F1A61B01A318Q50352802-AEE8A436-A21C-477F-B501-75907C559DEBQ50420474-8634350F-1655-4C18-B7B4-581A6E7CB5A1Q51448708-7DEAA7BE-F27A-47ED-82B7-189CAFEF12E2
P2860
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
@ast
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
@en
type
label
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
@ast
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
@en
prefLabel
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
@ast
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
@en
P2093
P2860
P50
P356
P1433
P1476
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
@en
P2093
Alberto Broniscer
Amar Gajjar
Arzu Onar-Thomas
Clinton F Stewart
Joshua Yew-Suang Lim
Jun J Yang
P2507
P2860
P2888
P304
P356
10.1038/NG.3217
P407
P577
2015-02-09T00:00:00Z